The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies
Open accessAbstract
Purpose Pre-clinical and early clinical data suggests the microbiome plays an important role in oncogenesis and influences response to immune checkpoint blockade (ICB). The objective of this systematic review and meta-analysis was to determine whether antibiotics affect overall survival (OS) and progression free survival (PFS) in patients with solid malignancies treated with ICB.Patients and methods A systematic search of EMBASE, MEDLINE and conference proceedings was conducted for observational studies examining the effect of antibiotics on ICB. A random effects study-level meta-analysis was performed with pooling of the hazards ratio (HR) for OS and PFS. Meta-regression was used to determine the impact of the timing of antibiotic exposure on OS.Results 766 studies were identified, and 18 studies met the inclusion criteria. Of the 2889 patients included, 826 (28.6%) were exposed to antibiotics. The most common malignancies were lung (59%), renal cell carcinoma (RCC) or urothelial carcinoma (16.3%) and melanoma (18.7%). OS was prolonged in those without antibiotic exposure (pooled HR 1.92, 95% CI 1.37-2.68, p < 0.001). The effect of antibiotics on OS was greater in studies defining antibiotic exposure as 42 days prior to initiation of ICB (HR 3.43, 95% CI 2.29-5.14, p < 0.0001). PFS was also longer in patients who did not receive antibiotics (pooled HR 1.65, 95% CI 1.3-2.1, p < 0.0001).Conclusion In patients receiving ICB, OS and PFS are longer in patients who are not exposed to antibiotics. Antibiotic use in the 42 days before starting ICB appears to be most detrimental to outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At the same time, retrospective studies have implicated that antibiotics were associated with decreased survival and attenuated response to ICI in patients with advanced solid tumors [39–44], supporting a causal link between antibiotic-induced dysbiosis and poor therapeutic efficacy of ICI.”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Self-citationThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0495-2 · Cited by 2,357
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908
Self-citationRecovery of gut microbiota of healthy adults following antibiotic exposure
Palleja, A., Mikkelsen, K. H., Forslund, S. K., Kashani, A., Allin, K. H., Nielsen, T., Hansen, T. H., Liang, S., Feng, Q., Zhang, C., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0257-9 · Cited by 875
Mining the Human Gut Microbiota for Immunomodulatory Organisms
Geva-Zatorsky, N., Sefik, E., Kua, L., Pasman, L., Tan, T. G., Ortiz-Lopez, A., Yanortsang, T. B., Yang, L., Jupp, R., Mathis, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.01.022 · Cited by 762
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740
Frankel, A. E., Coughlin, L. A., Kim, J., Froehlich, T. W., Xie, Y., Frenkel, E. P., & Koh, A. Y. (2017) · Neoplasia · doi:10.1016/j.neo.2017.08.004 · Cited by 709
Pinato, D. J., Howlett, S., Ottaviani, D., Urus, H., Patel, A., Mineo, T., Brock, C., Power, D., Hatcher, O., Falconer, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2785 · Cited by 626 · cited 1×
“[27] also stratified antibiotic exposure by timing, and found that the effects of antibiotics on survival were much greater in those exposed 0–30 days before initiation of immunotherapy (HR 7.”
BackgroundMaher, V. E., Fernandes, L. L., Weinstock, C., Tang, S., Agarwal, S., Brave, M., Ning, Y.-M., Singh, H., Suzman, D., Xu, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00318 · Cited by 331
Chalabi, M., Cardona, A., Nagarkar, D. R., Dhawahir Scala, A., Gandara, D. R., Rittmeyer, A., Albert, M. L., Powles, T., Kok, M., & Herrera, F. G. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.006 · Cited by 294
Elkrief, A., El Raichani, L., Richard, C., Messaoudene, M., Belkaid, W., Malo, J., Belanger, K., Miller, W., Jamal, R., Letarte, N., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1568812 · Cited by 208
Self-citationTinsley, N., Zhou, C., Tan, G., Rack, S., Lorigan, P., Blackhall, F., Krebs, M., Carter, L., Thistlethwaite, F., Graham, D., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0160 · Cited by 201
Ahmed, J., Kumar, A., Parikh, K., Anwar, A., Knoll, B. M., Puccio, C., Chun, H., Fanucchi, M., & Lim, S. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1507670 · Cited by 171
Zhao, S., Gao, G., Li, W., Li, X., Zhao, C., Jiang, T., Jia, Y., He, Y., Li, A., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.017 · Cited by 164
Impact of prior antibiotic use on the efficacy of nivolumab for non‑small cell lung cancer
Hakozaki, T., Okuma, Y., Omori, M., & Hosomi, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.9899 · Cited by 128
Antibiotic Use Does Not Appear to Influence Response to Nivolumab
Kaderbhaï, C., Richard, C., Fumet, J.-D., Aarnink, A., FOUCHER, P., Coudert, B. P., Favier, L., Lagrange, A., Limagne, E., Boidot, R., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11680 · Cited by 118
Lee, H., Quek, C., Silva, I., Tasker, A., Batten, M., Rizos, H., Lim, S. Y., Nur Gide, T., Shang, P., Attrill, G. H., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1537581 · Cited by 115
Ouaknine, J., de Tauriers, P. H., Duménil, C., Neveux, N., Dumoulin, J., Giraud, V., Labrune, S., Tisserand, J. C., Julié, C., Emile, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0658-1 · Cited by 109
Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients
van Vliet, M. J., Tissing, W. J. E., Rings, E. H. H. M., Koetse, H. A., Stellaard, F., Kamps, W. A., & de Bont, E. S. J. M. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22210 · Cited by 103
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma
Lalani, A.-K. A., Xie, W., Braun, D. A., Kaymakcalan, M., Bossé, D., Steinharter, J. A., Martini, D. J., Simantov, R., Lin, X., Wei, X. X., et al. (2020) · European Urology Oncology · doi:10.1016/j.euo.2019.09.001 · Cited by 100
Huemer, F., Rinnerthaler, G., Westphal, T., Hackl, H., Hutarew, G., Gampenrieder, S. P., Weiß, L., & Greil, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24751 · Cited by 94
Simmons, C. P. L., McMillan, D. C., Tuck, S., Graham, C., McKeown, A., Bennett, M., O’Neill, C., Wilcock, A., Usborne, C., Fearon, K. C. H., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0474 · Cited by 70
Sen, S., Pestana, R. C., Hess, K. R., Viola, G. M., & Subbiah, V. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy453 · Cited by 68
Rossi, G., Pezzuto, A., Sini, C., Tuzi, A., Citarella, F., McCusker, M. G., Nigro, O., Tanda, E. T., & Russo, A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.07.005 · Cited by 68
The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
Subbiah, V., & Kurzrock, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0519 · Cited by 43
Derosa, L., Routy, B., Enot, D. P., Baciarello, G., Massard, C., Loriot, Y., Fizazi, K. S., Escudier, B. J., Zitvogel, L., & Albiges, L. K. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.6_suppl.462 · Cited by 39
Self-citationMielgo-Rubio, X., Chara, L. E., Sotelo-Lezama, M. J., Castro, R. L., Rubio-Martínez, J., Velástegui, A., Olier, C., Falagán, S., Gómez-Barreda, I., Bautista-Sanz, P., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.395 · Cited by 30
Tinsley, N., Zhou, C., Villa, S., Tan, G., Lorigan, P. C., Blackhall, F. H., Elliott, T., Krebs, M., Carter, L., Thistlethwaite, F. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3010 · Cited by 26
Huemer, F., Rinnerthaler, G., Lang, D., Hackl, H., Lamprecht, B., & Greil, R. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz021 · Cited by 25
Thompson, J., Szabó, A., Arce-Lara, C. E., & Menon, S. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.926 · Cited by 23
Antibiotic use and overall survival in lung cancer patients receiving nivolumab.
Do, T. P., Hegde, A. M., Cherry, C. R., Stroud, C. R. G., Sharma, N. J., Cherukuri, S. D., Bowling, M., & Walker, P. R. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e15109 · Cited by 22
Kulkarni, A. A., Kumar, M., Pease, D. F., Wang, Y., DeFor, T. E., & Patel, M. R. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e20520 · Cited by 20
Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC).
Lalani, A. A., Xie, W., Lin, X., Steinharter, J. A., Martini, D. J., Duquette, A., Bossé, D., McKay, R. R., Simantov, R., Wei, X. X., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.607 · Cited by 16
Agarwal, A., Pond, G. R., Curran, C. R., Nassar, A. H., Nuzzo, P. V., Kumar, V., McGregor, B. A., Wei, X. X., Harshman, L. C., Choueiri, T. K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.435 · Cited by 13
Pinato, D. J., Howlett, S., Ottaviani, D., Urus, H., Patel, A., Mineo, T., Brock, C. S., Power, D., Hatcher, O., Falconer, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.8_suppl.147 · Cited by 13
Derosa, L., Routy, B., Mezquita, L., Naltet, C., Enot, D. P., Fidelle, M., Goubet, A., Soria, J., Massard, C., Goldwasser, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3015 · Cited by 12
Self-citationFailure is not final: ctDNA-guided rechallenge therapy in colorectal cancer
Siravegna, G., & Bardelli, A. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy525 · Cited by 11
Impact of antibiotic use on response to treatment with immune checkpoint inhibitors.
Khan, U., Peña, C., Brouwer, J., Hoffman, K., Choudhury, A. R., Zhang, C., Thakkar, P. V., Betel, D., Sarkar, S., Sonnenberg, G. F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.143 · Cited by 11
Masini, C., Berselli, A., Romagnani, A., Bonelli, C., Fantinel, E., Pagano, M., Banzi, M. C., Prati, G., Gasparini, E., Moretti, G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e14156 · Cited by 10
Hemadri, A., Huang, L., Lin, Y., Rose, A. E., Sander, C., Najjar, Y. G., Zarour, H. M., Kirkwood, J. M., & Davar, D. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9572 · Cited by 8
Kapoor, V., Runnels, J., Boyce, T. W., Pankratz, V. S., & Rixe, O. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e14141 · Cited by 7
Chalabi, M., Cardona, A. F., Nagarkar, D. R., Scala, A. M. D., Albert, M. L., Kok, M., Powles, T. B., & Herrera, F. G. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy486.001 · Cited by 6
Spakowicz, D. J., Husain, M., Tinoco, G., Patel, S. H., Burkart, J. T., Verschraegen, C. F., Kendra, K. L., Hoffman, S. E., Philippon, J., Quiroga, D. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.8_suppl.94 · Cited by 6
Metges, J., Michaud, E., Lagadec, D. D., Marhuenda, F., Chaslerie, A., & Grudé, F. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e15157 · Cited by 5
Weinstock, C., Maher, V. E., Fernandes, L. L., Tang, S. W., Agrawal, S., Brave, M. H., Ning, Y. M., Singh, H., Suzman, D. L., Xu, J. X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4557 · Cited by 4
Galli, G., Poggi, M. M., Fucà, G., Imbimbo, M., Proto, C., Signorelli, D., Vitali, M., Zilembo, N., Ganzinelli, M., de Braud, F., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.396 · Cited by 3
Zhao, S., Jia, Y., Jiang, T., Li, X., Li, W., Gao, G., Zhao, C., He, Y., Chen, X., Su, C., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.1728 · Cited by 2
Research works printed but not linked: 3
- Schett ARS, Mauti LA, Schmid S, Appenzeller C, Curioni-Fontecedro A, Frueh M, Joerger M (2019) Progsnotic impact of the use of antibiotics in patients with advanced non-small cell lung cancer receiving PD-(L)1 targeting monoclonal antibodies. Ann Oncol 30(Supplemental 2):157
- Derosa L, Routy B, Enot D, Fidelle M, Gubet AG, Goldwasser F, Zitvogel L, Loriot Y, Albiges L, Escudier B (2018) Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Kidney Cancer 2(Supplement 1):S24–S25
- Wilson BE, Routy B, Nagrial A, Chin V (2019) The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. Asia-Pacific J Clin Oncol 15(supplemental 9):359
Cited by
Butyrate-producing human gut symbiont, Clostridium butyricum , and its role in health and disease
Stoeva, M. K., Garcia-So, J., Justice, N., Myers, J., Tyagi, S., Nemchek, M., McMurdie, P. J., Kolterman, O., & Eid, J. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1907272 · Cited by 518
“Exposure to antibiotics prior to receiving ICB therapy is especially detrimental to the outcome.(124) Recently, first-in-human clinical trials showed that fecal microbiota transplantation (FMT) improved the efficacies of anti-PD-1 immunotherapy in patients with anti-PD-1-refractory metastatic melanoma, while also repr…”
BackgroundGut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
(2022) · doi:10.1186/s13045-022-01273-9 · Cited by 495
Hakozaki, T., Richard, C., Elkrief, A., Hosomi, Y., Benlaïfaoui, M., Mimpen, I., Terrisse, S., Derosa, L., Zitvogel, L., Routy, B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0196 · Cited by 316
Self-citationCancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 274
Messaoudene, M., Pidgeon, R., Richard, C., Ponce, M., Diop, K., Benlaifaoui, M., Nolin-Lapalme, A., Cauchois, F., Malo, J., Belkaid, W., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0808 · Cited by 250
Self-citation
Metadata
- Authors
- Wilson, B. E., Routy, B., Nagrial, A., & Chin, V. T.
- Affiliations
- UNSW Sydney (AU)
- Centre Hospitalier de l’Université de Montréal (CA)
- The University of Sydney (AU)
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Wilson, Brooke E.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2019-12-21
- Volume
- 69
- Issue
- 3
- Pages
- 343-354
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11027824
- OpenAlex
- W2995658490
- Cited by
- 152
- References
- 57
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 21 · 2023: 26 · 2022: 21 · 2021: 23 · 2020: 24 · 2019: 1
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- antibiotics, immune checkpoint blockade, gut microbiota, overall survival, progression-free survival, solid tumors, lung cancer, renal cell carcinoma, urothelial carcinoma, melanoma, cancer immunotherapy outcomes
- MeSH terms
- Anti-Bacterial Agents, Humans, Immunotherapy, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.